More on SWTX
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $46.99 |
|
|||
| Open | $46.99 | ||||
| 52 Wk High | $14.00 | ||||
| 52 Wk Low | $1.92 | ||||
| Day High | $46.99 | ||||
| Day Low | $46.99 | ||||
| P/E | 60.24 | ||||
| EPS | $0.78 | ||||
| Volume | 2,862,710 | ||||
- SpringWorks publishes long-term data on desmoid tumor drug OGSIVEO
- SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical On
- European Commission approves OGSIVEO for adults with desmoid tumors
- European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
- European Commission approves SpringWorks' EZMEKLY for rare tumor condition
- European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
- Form 15-12G SpringWorks Therapeutics
- Form SCHEDULE 13G SpringWorks Therapeutics Filed by: GLAZER CAPITAL, LLC
- Form 4 SpringWorks Therapeutics For: Jul 01 Filed by: Edris Badreddin
- Form 4 SpringWorks Therapeutics For: Jul 01 Filed by: LYNCH DANIEL
Entities mentioned with SWTX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- S1 | View Related Stories »
- Show More...
